Bank of America’s RenovoRx RNXT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-306
Closed -$257 6671
2025
Q4
$257 Buy
306
+14
+5% +$14 ﹤0.01% 6659
2025
Q3
$371 Sell
292
-66
-18% -$78 ﹤0.01% 7635
2025
Q2
$471 Buy
358
+54
+18% +$62 ﹤0.01% 7677
2025
Q1
$301 Buy
304
+108
+55% +$126 ﹤0.01% 7613
2024
Q4
$253 Hold
196
﹤0.01% 7541
2024
Q3
$208 Buy
196
+14
+8% +$16 ﹤0.01% 7558
2024
Q2
$206 Buy
+182
New +$224 ﹤0.01% 7557
2024
Q1
Sell
-118
Closed -$270 8111
2023
Q4
$270 Buy
+118
New +$113 ﹤0.01% 7338
2023
Q1
Sell
-14
Closed -$32 8200
2022
Q4
$32 Sell
14
-33,612
-100% -$64.2K ﹤0.01% 7891
2022
Q3
$68K Sell
33,626
-14,798
-31% -$32.2K ﹤0.01% 6537
2022
Q2
$96K Buy
48,424
+33,622
+227% +$68.7K ﹤0.01% 6500
2022
Q1
$44K Buy
+14,802
New +$51.8K ﹤0.01% 7228
2021
Q4
Sell
-100
Closed -$1K 8575
2021
Q3
$1K Buy
+100
New +$833 ﹤0.01% 8001

Other funds holding RNXT

Bank of America's RNXT Position: Q1 2026 in Review

Bank of America sold out of RenovoRx (RNXT) in Q1 2026, closing a stake of 306 shares — an estimated $257 sold.

Bank of America first reported a position in RNXT in Q3 2021 and held it in 13 quarters. The position peaked at $96K in Q2 2022. 31 funds tracked by Wall St. Rank hold RNXT as of Q1 2026.

  • Bank of America reported no remaining RenovoRx position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 306 RenovoRx shares in Q1 2026, an estimated $257.
  • Bank of America first reported a position in RenovoRx in Q3 2021 and held it in 13 quarters.
  • Bank of America's RenovoRx position peaked at $96K in Q2 2022.
  • 31 funds tracked by Wall St. Rank held RenovoRx as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.